– Honor’s combined expertise in product management and strategy uniquely positions it to lead M2GEN’s next phase of growth as a digital oncology healthcare platform company focused on customer-centric innovation. .
TAMPA, Florida., July 12, 2022 /PRNewswire/ — M2GEN, a bioinformatics company accelerating discoveries in oncology research through cutting-edge data and analytics, today announced the appointment of Melissa Honor, MPH, to its management team as Chief Product Officer. In this role, Honor will be responsible for accelerating the value of M2GEN’s oncology discovery data products, tools and services for research and industrial partners by expanding the company’s product management functions, including strategy product management, product design and product management operations.
The addition of Honor to the leadership team further reinforces M2GEN’s commitment to providing differentiated analytics solutions for oncology research by attracting and developing world-class talent, and builds on the significant investment in the Clayton, Dubilier & Rice organization in 2021.
“We are thrilled to have Melissa join our team as Chief Product Officer,” said Jim Gabrielle, President and CEO of M2GEN. “Melissa is an accomplished product management executive who has focused her career on building high-performing product teams at the intersection of data, technology, and healthcare. She joins a strong leadership team that is fully prepared to drive continued impact for patients and success for M2GEN,” said Gabriele.
M2GEN remains focused on its goal of transforming patient outcomes by providing products, solutions and data services that drive cutting-edge scientific research and drug discovery through precision medicine. “The addition of Melissa is a key step in the continued advancement of our strategic growth plan, bringing expanded product design and development capabilities that will benefit our partners and patients,” said Gabriele. “Melissa’s experience will also allow us to take full advantage of the world-class life sciences technology platform we are building together with Microsoft.”
“I am beyond excited to join the M2GEN team and play a leadership role in driving the company’s product strategy and design,” added Honor. “M2GEN’s unique clinicogenomic data assets and synergy with its oncology research information exchange network® (ORIEN®) provide a solid foundation that will allow us to rapidly evolve our products to optimize value for our research partners and suppliers on behalf of the patients we serve, ultimately connecting those patients to treatments tailored to the unique biology of their sickness.
Honor is a tenacious and accomplished product management executive who is focused on building high performing teams and driving a business strategy based on innovation, advanced analytics and operational excellence. Most recently, she served as Vice President, Product Management at Ontada, with responsibility for developing and managing its precision medicine and community oncology portfolio. In this role, she optimized value for life science suppliers and customers by creating a product management organization and roadmap focused on getting the right information to the right person at the right time. She also expanded product offerings to increase adoption of genomic ordering and access to research results.
Honor has over 15 years of experience managing products that support provider care delivery, population health and research. She holds a Bachelor of Science in Health Psychology from the University of South Floridaa Master of Public Health in Epidemiology from the Boston School of Public Health and a Graduate Certificate in Biomedical Informatics from Oregon Health Science University.
M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytical tools. The company’s innovative dataset accelerates the discovery, development and delivery of personalized therapies. M2GEN Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-designated cancer centers that collect anonymized, lifelong consented clinical and genomic patient data for research purposes, enables a collaborative approach to cancer control for patients at today and tomorrow. M2GEN currently has more than 325,000 total consenting patients in a network of 18 cancer centers in 10 states. Learn more at www.m2gen.com and follow us on LinkedIn and Twitter.